Our company was founded on the idea that the research and development of innovative medicines could be accelerated. Within a decade, we discovered and secured global approvals for two breakthrough medicines and assembled a promising pipeline of investigational therapies.

Today, we are bolder and more ambitious than ever before in our effort to improve and extend the lives of many more patients with serious diseases.

A look inside our labs

Our scientists merge expertise in bioinformatics, structural and cell biology, and world-class drug design capabilities to advance our discovery portfolio. Our approach enables us to rapidly identify compelling disease targets and design innovative therapies that treat root causes of disease.

The result is a robust and diverse portfolio of clinical- and research-stage programs in allergy/inflammation and oncology/hematology. With a steadfast commitment to scientific excellence and to patients, we aim to rapidly and unequivocally change the face of medicine.

Founded on the belief that the research and development of innovative medicines could be accelerated, we have used our proprietary scientific platform to develop potent and selective inhibitors for highly sought-after targets.